1. [Complete radical prostatectomy and positive lymph nodes (stages pT1 to 4, N1 to 3, M0, D1)].
- Author
-
Feyaerts A, Stainier L, Nollevaux MC, De Groote P, Lorge F, Opsomer R, Wese FX, Cosyns JP, and Van Cangh P
- Subjects
- Adenocarcinoma drug therapy, Adenocarcinoma pathology, Adenocarcinoma secondary, Antineoplastic Agents, Hormonal therapeutic use, Chemotherapy, Adjuvant, Disease Progression, Disease-Free Survival, Follow-Up Studies, Humans, Lymph Node Excision, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Prostate-Specific Antigen blood, Prostatic Neoplasms drug therapy, Prostatic Neoplasms pathology, Retrospective Studies, Risk Factors, Survival Rate, Adenocarcinoma surgery, Lymphatic Metastasis pathology, Prostatectomy methods, Prostatic Neoplasms surgery
- Abstract
Lymph node metastases are rarely detected during radical prostatectomy (55/647 patients in our series or 8.5%) and several authors consider that lymphadenectomy is unnecessary in most cases. Criteria based on clinical stage, PSA and tumor grade have been elaborated in order to avoid pelvic lymph node dissection in a low risk population. It is commonly admitted that patients with clinically localized prostate cancer, a PSA level < 10 ng/ml, and a Gleason score < 7 could be spared a pelvic lymphadenectomy. In our series, these patients account for 12% of positive nodes. The best treatment for prostate cancer patients with a nodal disease is controversial. We compare the evolution of two groups of patients: radical prostatectomy alone or combined with an immediate adjuvant hormonal treatment. We observe a difference between the two groups for biological progression (PSA failure) but not yet for clinical progression nor for survival as our mean follow-up in only 6 years.
- Published
- 1998